{
  "docId": "019de076-f846-767d-9b7f-8682a04c3e89",
  "docSlug": "d28195e1bb64bc51ad898953c5c30263",
  "documentTitle": "Boundless Bio | IPO Presentation Deck | 51 slides",
  "authorId": "boundless-bio",
  "authorName": "Boundless Bio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 39,
  "pageCount": 51,
  "prevPage": 38,
  "nextPage": 40,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a biological mechanism diagram to explain the therapeutic rationale for BBI-825.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-f846-767d-9b7f-8682a04c3e89/39",
  "deckHref": "/decks/019de076-f846-767d-9b7f-8682a04c3e89",
  "deckJsonHref": "/decks/019de076-f846-767d-9b7f-8682a04c3e89.json",
  "deckAnchorHref": "/decks/019de076-f846-767d-9b7f-8682a04c3e89#slide-39",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.33,
        "x": 0.62,
        "y": 0.285
      },
      "kind": "callout",
      "text": "BBI-825: RNR selective, Orally available, Favorable ADME, Developed with precision medicine approach. Although approved non-selective agents gemcitabine and hydroxyurea possess inhibitory activity against RNR, there are currently no selective RNR inhibitors in clinical development",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a26103f6-e45d-407e-b9de-bee55ec0d726",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.48,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "diagram",
      "text": "Reliance on RNR is elevated in ecDNA-enabled cells",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7aa9f8e6-b690-4904-8dec-1fcf79b9a254",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.48,
        "x": 0.05,
        "y": 0.65
      },
      "kind": "list",
      "text": "RNR: rate-limiting enzyme responsible for de novo synthesis of dNTPs, the building blocks of DNA, including assembly and repair of ecDNA. Therapeutic inhibition of RNR dysregulates dNTP production and creates synthetic lethality in ecDNA+ tumor cells",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d29c081-6fe8-42a9-a0d5-4bcd01ba3076",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "ADME: absorption, distribution, metabolism and excretion; dNTPs: deoxyribonucleotide triphosphates",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce87e6e9-46a9-47d9-9c48-24ee7fb2f456",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Our second ecDTx, BBI-825, is a novel ribonucleotide reductase (RNR) inhibitor that targets the assembly and repair of ecDNA",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b782b92b-c941-4247-b9fa-05591ba3200e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "synthetic-lethality",
      "slug": null,
      "matchId": "238b6396-ac87-4742-a442-73f494f301a6",
      "evidence": "Therapeutic inhibition of RNR dysregulates dNTP production and creates synthetic lethality in ecDNA+ tumor cells",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}